Short answer
Vertex Pharmaceuticals (VRTX) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 consolidated financial results reported for the three months ended March 31, 2026.
Vertex Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 consolidated financial results reported for the three months ended March 31, 2026
- Press release issued May 4, 2026 and included as Exhibit 99.1
- Exhibit contains the substantive financial details investors should review for performance assessment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vertex Pharmaceuticals 8-K filings
Get the next VRTX 8-K as it lands
Follow VRTX for push alerts, or ask the research agent what this filing means.